leisure time -WSS

leisure time

author：focus 2025-09-29 01:37:38 - browse：995

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Micronoma's microbiome cancer diagnostic approach under fire

focus

WSS

Adults seen as increasingly susceptible to measles

The painfully weak evidence on taking collagen to treat arthritis

Germany receives 178 compensation applications from gay servicepeople over discrimination

Wildfire pollution widens asthma inequities on Long Island

Adults seen as increasingly susceptible to measles

Hospitals use virtual reality to design more inclusive rooms for kids

focus

leisure time

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

What does generative AI mean for health care? We asked experts

Trump indictment: Who are the 'co

Hollywood unions extend contract negotiations for actors

EQRx, failed developer of low

Dobbs anniversary: the lost opportunity of abortion as health care

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

The cancer drug shortage isn’t new — and neither are the solutions

New safety details link Apellis eye drug to rare cases of blindness

knowledge

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Vertex non

‘The Bear’ and hospitality in hospitals

NIH launches clinical trials and new research office for long Covid

Micronoma's microbiome cancer diagnostic approach under fire

entertainment

focus

focus

focus